Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Majeed, R ^a   Hamid, A ^a   Sangwan, P L ^a   Chinthakindi, P K ^a   Koul, S ^a   Rayees, S ^a   Singh, G ^a   Mondhe, D M ^a   Mintoo, M J ^a   Singh, S K ^a   Rath, S K ^a   Saxena, A K ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 [ 1 N ( HYDROXYNAPHTH 1 YL) 1H 1,2,3 TRIAZOL 4 YL]METHYLOXY BETULINIC ACID; ANTINEOPLASTIC AGENT; BETULIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE; CYCLINE; CYTOCHROME C; DNA; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; NAPHTHOL DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110 ALPHA; PROTEIN P85 ALPHA; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TERPENOID DERIVATIVE; TRIAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; TRITERPENE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER CELL LINE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG SAFETY; EHRLICH ASCITES TUMOR; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; TRITERPENES;

EID: 84921058051     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.387     Document Type: Article

References (48)

1. Fernandes J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA, Gattass CR. Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 2003; 190: 165-169.
2. Jassim S, Naji MA. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003; 95: 412-427.
3. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3: 509-520.
4. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007; 9: 767-776.
5. Gao Y, Jia Z, Kong X, Li Q, Chang DZ,Wei D et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011; 71: 5182-5193.
6. Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC, Safe S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a: ZBTB10. Mol Carcinog 2013; 52: 591-602.
7. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009; 14: 885-890.
8. Tan Y, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 2003; 9:2866-2875.
9. Kasperczyk H, La Ferla-Br?hl K, Westhoff MA, Behrend L, Zwacka RM, Debatin K-M et al. Betulinic acid as new activator of NF-?B: molecular mechanisms and implications for cancer therapy. Oncogene 2005; 24: 6945-6956.
10. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M et al. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
11. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
12. Rzeski W, Stepulak A, Szymanski M, Sifringer M, Kaczor J, Wejksza K et al. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol 2006; 374:11-20.
13. Chang F, Lee J, Navolanic P, Steelman L, Shelton J, BlalockWet al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603.
14. Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S et al. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One 2012; 7: e46853.
15. Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher CW et al. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice1. Biopharm Drug Dispos 1999; 20: 379-383.
16. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs 2008; 26: 25-34.
17. Kvasnica M, Sarek J, Klinotova E, Dzubak P, Hajduch M. Synthesis of phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med Chem 2005; 13: 3447-3454.
18. Gauthier C, Legault J, Lavoie S, Rondeau S, Tremblay S, Pichette A. Synthesis and cytotoxicity of bidesmosidic betulin and betulinic acid saponins. J Nat Prod 2008; 72:72-81.
19. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs 2008; 26: 25-34.
20. Majeed R, Sangwan PL, Chinthakindi PK, Khan I, Dangroo NA, Thota N et al. Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents. Eur J Med Chem 2013; 63: 782-792.
21. da Silva I, Martins P, da Silva E, Ferreira S, Ferreira V, da Costa K et al. Synthesis of 1H-1, 2, 3-triazoles and study of their antifungal and cytotoxicity activities. Med Chem 2013; 9:1085-1090.
22. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32-50.
23. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
24. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
25. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
26. Momiyama M, Suetsugu A, Kimura H, Chishima T, Bouvet M, Endo I et al. Dynamic subcellular imaging of cancer cell mitosis in the brain of live mice. Anticancer Res 2013; 33:1367-1371.
27. Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nat Protoc 2006; 1: 775-782.
28. Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H et al. Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res 2004; 64: 4251-4256.
29. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13:1899-1911.
30. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
31. Creton S, Dewhurst IC, Earl LK, Gehen SC, Guest RL, Hotchkiss JA et al. Acute toxicity testing of chemicals-Opportunities to avoid redundant testing and use alternative approaches. Crit Rev Toxicol 2010; 40: 50-83.
32. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
33. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006; 66: 3347-3350.
34. Huttunen KM, Raunio H, Rautio J. Prodrugs-from serendipity to rational design. Pharmacol Rev 2011; 63: 750-771.
35. Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 2010; 12: 87-94.
36. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
37. Qazi AK, Hussain A, Hamid A, Qurishi Y, Majeed R, Ahmad M et al. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies. Anticancer Agents Med Chem 2013; 13: 1552-1564.
38. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000; 100: 71-78.
39. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci 2001; 98: 9666-9670.
40. Fang X, Yu S, Eder A, Mao M, Bast Jr RC, Boyd D et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18:6635-6640.
41. Karin M, Delhase M. The I?B kinase (IKK) and NF-?B: key elements of proinflammatory signalling. Semin Immunol 2000; 2000: 85-98.
42. Yu Z, Li W. Induction of apoptosis by puerarin in colon cancer HT-29 cells. Cancer Lett 2006;238: 53-60.
43. Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995; 184: 39-51.
44. Crow JP. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1997; 1: 145-157.
45. Lin H-I, Lee Y-J, Chen B-F, Tsai M-C, Lu J-L, Chou C-J et al. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 2005; 230: 248-259.
46. Thanabhorn S, Jaijoy K, Thamaree S, Ingkaninan K, Panthong A. Acute and subacute toxicity study of the ethanol extract from Lonicera japonica Thunb. J Ethnopharmacol 2006;107: 370-373.
47. Rayees S, Sharma R, Singh G, Najar IA, Singh A, Ahamad DB et al. Acute, sub-acute and general pharmacological evaluation of 5-(3, 4-methylenedioxyphenyl)-4-ethyl-2E, 4E-pentadienoic acid piperidide (SK-20): a novel drug bioavailability enhancer. Environ Toxicol Pharmacol 2013; 35: 347-359.
48. Brock WJ, Schroeder RE, McKnight CA, VanSteenhouse JL, Nyberg JM. Oral repeat dose and reproductive toxicity of the chlorinated flame retardant Dechlorane Plus. Int J Toxicol 2010; 29: 582-593.